IFPMA’s Post

💻💊 #Axioma by #ProximaResearch has database of healthcare professionals (HCPs) and organizations (HCOs), which provides vital insights for targeted marketing strategies 👥 Key indicators like “patient flow” and “call pressure”: patient flow reveals the average number of patients seen by a doctor weekly, pinpointing those with significant prescribing influence, and call pressure indicates the frequency of visits from medical representatives 📊 Regularly updated data ensures timely access to the latest information, allowing for agile responses to market trends    📍 With targeted campaigns fueled by comprehensive insights, businesses can drive growth and success in the competitive pharmaceutical landscape   📲 Learn more via link: http://surl.li/symoc #pharmacy #pharmacieuticalmarket #database #data 

Preventative medicine is set to become the next major shift in healthcare, offering improved health outcomes for individuals and society while lowering treatment costs. It also has the potential to drive significant profits for pharmaceutical companies. Our latest Viewpoint explores 4 strategies that can unlock the power of preventative medicine. Follow the link to our website to learn more https://lnkd.in/eyHxciUv #healthcare #preventative #medicine #strategy #research #pharmaceutical #business

The innovative pharmaceutical industry collaborates all over the world to strengthen health systems today and ensure better #globalhealth security for tomorrow. #HealthforAll is why the innovative pharmaceutical industry is collaborating toward #GlobalHealthProgress and #UniversalHealthCoverage.  This #UHCDay, the pharma industry urges leaders to adopt inclusive, participatory health frameworks. https://ifpma.info/40QVYwU  IFPMA | UHC2030 - Taking action for universal health coverage

Key Opinion Leaders (KOLs) play a crucial role in the pharmaceutical industry by influencing medical professionals, researchers, and the broader healthcare industry. Establishing a ranking for KOLs involves evaluating various factors, including expertise, publication records, clinical trial experience, patient advocacy, peer recognition, and influence within the industry. PharmaScroll's TreasureTell database offers a comprehensive and unbiased KOL ranking system tailored to the specific requirements of our clients. Learn more: https://lnkd.in/dNqX95J3 #PharmaScroll #healthcare #pharmaceutical #keyopinionleader #database #TreasureTell #kol #dashboard #expertinsights #socialmedia #dataanalytics #healthcareinsights #businessintelligence #research

Repairing the Patient Journey: How Pharma Can Fix the Obvious–and Not So Obvious–Breaking Points of Nonadherence: Today’s guest post comes from Maria Kirsch, President, Patient Services, Krista Pinto, President, Deployment Solutions, and Mike Scott, Senior Vice President, Specialty Consulting at EVERSANA. Maria, Krista, and Mike discuss the key reasons why patients abandon drug therapy. They then describe EVERSANA’s approach for helping manufacturers and healthcare providers improve adherence and health outcomes. Learn more about EVERSANA’s solutions from this complimentary whitepaper: Repairing the Patient Journey: How Pharma Can Fix the Obvious–and Not So Obvious–Breaking Points of Nonadherence. Read on for the authors’ insights. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only. #pbm #drugpricing #pharmaceutical

Addressing diversity gaps in #clinicaltrials is crucial for equitable #healthcare outcomes. While recent government guidance is a step forward, pharmaceutical companies must take proactive steps now. Our CEO Ariel Katz predicts three factors that will fuel a massive transformation in clinical trial diversity in his article for Society for Clinical Research Sites (SCRS): https://hubs.la/Q02kbGDN0 #ClinicalTrials #Diversity #Pharma

Addressing diversity gaps in #clinicaltrials is crucial for equitable #healthcare outcomes. While recent government guidance is a step forward, pharmaceutical companies must take proactive steps now. Our CEO Ariel Katz predicts three factors that will fuel a massive transformation in clinical trial diversity in his article for Society for Clinical Research Sites (SCRS): https://hubs.la/Q02kRZ_Q0 #clinicaltrials #diversity #pharma

#NewPublication: 'Transformative Policies to Realise Universal Access to Medicines' https://lnkd.in/dNNkKgtW Our publication 📘 highlights the critical need for innovative, non-commercial approaches to pharmaceutical research, development and distribution. It advocates for knowledge sharing and public ownership to ensure that everyone, regardless of economic status, has access to essential medicines. 🌍 Our publication critically examines the limitations of profit-driven models in the pharmaceutical industry and proposes #OpenScience and public pharmaceutical institutions as viable solutions. This is a call to action for policymakers, #Healthcare professionals, and global #Health advocates to prioritise #HumanRights and #PublicHealth goals over commercial interests. It is a must-read for those dedicated to transforming healthcare access globally! 💡 #RightToHealth #HumanRights

KOLs play a pivotal role in bridging the gap between pharmaceutical companies, healthcare providers, and patients, contributing to advancements in medical science, improved patient outcomes, and the responsible use of medications. PharmaScroll's TreasureTell database offers a comprehensive KOL analytics platform, providing clients with a wealth of data on KOLs in various therapy areas. It enables effective KOL identification, profiling, ranking, and network mapping while monitoring their activities and online presence. Learn More: https://lnkd.in/dFtbedKc #PharmaScroll #healthcare #pharmaceutical #digital #keyopinionleaders #treasuretell #socialmedia #engagement #research #insights #expertinsights #analytics

As we aim to ensure that physicians understand innovative therapies and patients receive the most suitable medications, it's important to recognize that a targeted approach to communications by pharmaceutical companies can enhance these goals. Take a moment to explore my article, where I discuss how behavioural science could transform healthcare communications, empowering patients to make informed choices and guiding physicians in adopting new treatments. In today's fast-paced healthcare landscape, understanding human behaviour is crucial. Behavioural science is more than just theories—it's a powerful tool that helps pharmaceutical companies tailor cost-effective communication strategies, equips physicians with knowledge on cutting-edge therapies, and empowers patients to take control of their health journey like never before. Join the conversation and learn how behavioural science is reshaping patient care, engaging physicians, and driving pharmaceutical innovation. Don't miss the chance to leverage the potential of behavioural science for a healthier, more informed future. #HealthcareInnovation #BehaviouralScience #PatientCare #PrescriberInertia